Prior to joining Gene Express, Lester worked at Pfizer in its Global Research and Development and Global Pharmaceutical groups. Before that he was director of clinical technologies for experimental medicine at Pharmacia.
Kevin Harley, Tim Orpin, Richard Shen, Piet Borst, Jose Baselga, Matt van de Rijn, David Kerr, Kent Osbourne, Joe Gray, Laura van ‘t Veer, David Lester
Illumina announced a number of personnel changes during its third-quarter conference call last week.
Kevin Harley has joined the firm as vice president of human resources. He previously held a similar position at Intralase. Before Intralase, Harley worked at Edwards Lifesciences and Baxter Healthcare, Illumina said.
Tim Orpin has also joined the company as general manager of Asia Pacific and Japan. Orpin served previously as vice president, Asia Pacific, for Applied Biosystems.
Additionally, Illumina said that Richard Shen has been promoted to vice president of assay biochemistry and reagent manufacturing. He previously served as senior director of array biochemistry.
Agendia this week appointed six members to its newly established clinical and scientific advisory board.
The company said that the board will be chaired by Piet Borst, emeritus director of the Netherlands Cancer Institute. The other five seats are held by Jose Baselga, chairman of the medical oncology service at Vall d'Hebron University Hospital in Barcelona; Matt van de Rijn, professor of pathology at Stanford University; David Kerr, professor of clinical pharmacology at the University of Oxford; Kent Osborne, director of the Duncan Cancer Center at Baylor College of Medicine; and Joe Gray, director of the Life Sciences Division at Lawrence Berkeley National Laboratory in Berkeley, Calif.
Separately, Agendia last week said that Laura van 't Veer, its chief research officer, has received a 2007 Breast Cancer Research Foundation Award from the Pink Ribbon Breast Cancer Research Foundation.
Gene Express recently appointed David Lester as senior vice president of strategy and corporate development.